Neoantigen-specific TCR-T Cell-based Immunotherapy for Acute Myeloid Leukemia

Overview

Journal Exp Hematol Oncol

Publisher Biomed Central

Specialty Hematology

Date 2022 Nov 17

PMID 36384590

Authors

Weijun Zhou

Jinyi Yu

Yilu Li

Kankan Wang

Affiliations

Soon will be listed here.

Abstract

Neoantigens derived from non-synonymous somatic mutations are restricted to malignant cells and are thus considered ideal targets for T cell receptor (TCR)-based immunotherapy. Adoptive transfer of T cells bearing neoantigen-specific TCRs exhibits the ability to preferentially target tumor cells while remaining harmless to normal cells. High-avidity TCRs specific for neoantigens expressed on AML cells have been identified in vitro and verified using xenograft mouse models. Preclinical studies of these neoantigen-specific TCR-T cells are underway and offer great promise as safe and effective therapies. Additionally, TCR-based immunotherapies targeting tumor-associated antigens are used in early-phase clinical trials for the treatment of AML and show encouraging anti-leukemic effects. These clinical experiences support the application of TCR-T cells that are specifically designed to recognize neoantigens. In this review, we will provide a detailed profile of verified neoantigens in AML, describe the strategies to identify neoantigen-specific TCRs, and discuss the potential of neoantigen-specific T-cell-based immunotherapy in AML.

Citing Articles

A therapeutic regimen using neoantigen-specific TCR-T cells for HLA-A*2402-positive solid tumors.

Bei Y, Huang Y, Wu N, Li Y, Xu R, Liu B EMBO Mol Med. 2025; 17(2):365-383.

PMID: 39748060 PMC: 11821884. DOI: 10.1038/s44321-024-00184-1.

Molecular mimicry as a mechanism of viral immune evasion and autoimmunity.

Maguire C, Wang C, Ramasamy A, Fonken C, Morse B, Lopez N Nat Commun. 2024; 15(1):9403.

PMID: 39477943 PMC: 11526117. DOI: 10.1038/s41467-024-53658-8.

Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia.

Kheirkhah A, Habibi S, Yousefi M, Mehri S, Ma B, Saleh M Front Immunol. 2024; 15:1460437.

PMID: 39411712 PMC: 11474923. DOI: 10.3389/fimmu.2024.1460437.

Breaking Boundaries: Immunotherapy for Myeloid Malignancies.

Gavrilova T, Schulz E, Mina A Cancers (Basel). 2024; 16(16).

PMID: 39199554 PMC: 11352449. DOI: 10.3390/cancers16162780.

Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.

Sotirov S, Dimitrov I Int J Mol Sci. 2024; 25(9).

PMID: 38732150 PMC: 11084719. DOI: 10.3390/ijms25094934.

References

RAMMENSEE H, Bachmann J, Emmerich N, Bachor O, Stevanovic S . SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999; 50(3-4):213-9. DOI: 10.1007/s002510050595. View

Fernandez-Poma S, Salas-Benito D, Lozano T, Casares N, Riezu-Boj J, Mancheno U . Expansion of Tumor-Infiltrating CD8 T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. Cancer Res. 2017; 77(13):3672-3684. DOI: 10.1158/0008-5472.CAN-17-0236. View

McMahon C, Ferng T, Canaani J, Wang E, Morrissette J, Eastburn D . Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2019; 9(8):1050-1063. DOI: 10.1158/2159-8290.CD-18-1453. View

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

Heath E, Chan S, Minden M, Murphy T, Shlush L, Schimmer A . Biological and clinical consequences of NPM1 mutations in AML. Leukemia. 2017; 31(4):798-807. DOI: 10.1038/leu.2017.30. View

Malekzadeh P, Yossef R, Cafri G, Paria B, Lowery F, Jafferji M . Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. Clin Cancer Res. 2020; 26(6):1267-1276. PMC: 7424598. DOI: 10.1158/1078-0432.CCR-19-1874. View

He Q, Jiang X, Zhou X, Weng J . Targeting cancers through TCR-peptide/MHC interactions. J Hematol Oncol. 2019; 12(1):139. PMC: 6921533. DOI: 10.1186/s13045-019-0812-8. View

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

10.

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

11.

Hoof I, Peters B, Sidney J, Pedersen L, Sette A, Lund O . NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 2008; 61(1):1-13. PMC: 3319061. DOI: 10.1007/s00251-008-0341-z. View

12.

Graf C, Heidel F, Tenzer S, Radsak M, Solem F, Britten C . A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood. 2006; 109(7):2985-8. DOI: 10.1182/blood-2006-07-032839. View

13.

Petrov J, Wada M, Pinz K, Yan L, Chen K, Shuai X . Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia. 2018; 32(6):1317-1326. PMC: 5990523. DOI: 10.1038/s41375-018-0075-3. View

14.

Matsuda T, Leisegang M, Park J, Ren L, Kato T, Ikeda Y . Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018; 24(21):5357-5367. DOI: 10.1158/1078-0432.CCR-18-0142. View

15.

Wang T, Wang L, Alam S, Hoeppner L, Yang R . ScanNeo: identifying indel-derived neoantigens using RNA-Seq data. Bioinformatics. 2019; 35(20):4159-4161. DOI: 10.1093/bioinformatics/btz193. View

16.

Liepe J, Marino F, Sidney J, Jeko A, Bunting D, Sette A . A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science. 2016; 354(6310):354-358. DOI: 10.1126/science.aaf4384. View

17.

Alsafadi S, Houy A, Battistella A, Popova T, Wassef M, Henry E . Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016; 7:10615. PMC: 4743009. DOI: 10.1038/ncomms10615. View

18.

Zhang Y, Ma J, Zhang H, Jiang Y, Luo W . Cancer vaccines: Targeting KRAS-driven cancers. Expert Rev Vaccines. 2020; 19(2):163-173. DOI: 10.1080/14760584.2020.1733420. View

19.

Deniger D, Pasetto A, Robbins P, Gartner J, Prickett T, Paria B . T-cell Responses to "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. Clin Cancer Res. 2018; 24(22):5562-5573. PMC: 6239943. DOI: 10.1158/1078-0432.CCR-18-0573. View

20.

Blass E, Ott P . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021; 18(4):215-229. PMC: 7816749. DOI: 10.1038/s41571-020-00460-2. View